Trulicity vs Ozempic: Mechanism, Dosing, and Data

Published May 25, 2026Updated May 27, 2026Last reviewed May 25, 2026

For the broader cluster context, see the semaglutide vs Ozempic and Wegovy comparison hub.

Author: HealthRX Editorial Team Medically reviewed by: Dr. Mark Halpern, MD (Internal Medicine, Obesity Medicine) Last clinical review: May 2026

Compounded semaglutide is not FDA-approved. This article is patient education and does not replace consultation with a licensed clinician.

Last March, a 52-year-old accountant named David in suburban Phoenix sat across from his endocrinologist with two prior authorizations spread on the desk between them. One was for Trulicity. The other for Ozempic. His A1c was 8.1, his BMI was 34, and his insurer had approved dulaglutide but denied semaglutide. "My doctor said both would help my blood sugar," David told me, "but that one was clearly better for weight loss. The insurance company didn't seem to care about that part." His situation isn't unusual. It's the situation that drives most of the search traffic behind "trulicity vs ozempic," and it deserves a better answer than the marketing copy provides.

This guide sits inside the broader Compounded Semaglutide vs Ozempic and Wegovy cluster, which is part of the compounded semaglutide pillar guide.

Two Molecules, One Drug Class, Very Different Track Records

Let's get the basics out of the way. Trulicity is the brand name for dulaglutide. Ozempic is the brand name for semaglutide. Both are once-weekly subcutaneous GLP-1 receptor agonists approved for type 2 diabetes. Both reduce blood sugar. Both cause weight loss. Both make some people nauseous. And that's roughly where the similarities stop being interesting and the differences start mattering.

Semaglutide has a second life as Wegovy, the higher-dose formulation approved specifically for chronic weight management. Dulaglutide does not have an equivalent weight-loss indication. This isn't an accident of marketing strategy. It reflects what the trial data showed.

In the SUSTAIN-7 trial, semaglutide 1.0 mg weekly was compared head-to-head against dulaglutide 1.5 mg weekly in patients with type 2 diabetes over 40 weeks. Semaglutide produced greater A1c reductions and greater weight loss. Both drugs had GI side effects as the primary tolerability concern.

Here's the thing: SUSTAIN-7 compared the top approved diabetes doses of each drug. Semaglutide had a clear edge on both glycemic control and body weight at those doses. That's a meaningful finding, not a statistical technicality.

The Weight Loss Data That Changed the Conversation

The reason semaglutide dominates online discussion isn't really about diabetes management. It's the STEP program.

STEP-1 tested semaglutide 2.4 mg weekly against placebo over 68 weeks and reported a mean 14.9 percent weight loss from baseline in the active arm. That number was large enough to rewrite how obesity medicine physicians think about pharmacotherapy.

STEP-3 layered a structured lifestyle intervention (intensive behavioral therapy, meal replacements, exercise counseling) on top of the same protocol and produced even greater mean weight loss. The takeaway is that the drug alone does significant work, but lifestyle programming is additive, not decorative.

STEP-4 answered the question patients always ask: what happens if I stop? Patients who switched from active semaglutide to placebo at week 20 experienced partial weight regain over the subsequent 48 weeks. This result surprised no one in obesity medicine but disappointed a lot of patients. Weight regulation is chronic biology. It behaves like blood pressure or thyroid function: remove the intervention, and the underlying condition reasserts itself.

Dulaglutide simply doesn't have equivalent weight-loss trial data at these doses and durations. That's the core reason the "trulicity vs ozempic" comparison, when people are really asking about weight, tilts heavily toward semaglutide.

Cardiovascular Evidence: Where Semaglutide Pulled Further Ahead

For patients with established cardiovascular disease, the data separation widened further in 2023.

SUSTAIN-6 and the broader LEADER program (which tested liraglutide, a related GLP-1) established the cardiovascular safety of this drug class. But the SELECT trial went further. It tested semaglutide 2.4 mg weekly in patients with established cardiovascular disease and overweight or obesity, without diabetes, and reported a 20 percent relative reduction in major adverse cardiovascular events. That's not just safety. That's benefit.

Dulaglutide has its own cardiovascular outcomes trial (REWIND), which showed risk reduction in a broader diabetic population, including patients at lower cardiovascular baseline risk. It's a credible result. But SELECT's findings in a non-diabetic population with obesity specifically gave semaglutide a differentiator that dulaglutide currently can't match.

My honest read: if a patient has both obesity and cardiovascular risk, semaglutide is the stronger evidence-based choice. The data aren't ambiguous on this one.

Where Compounded Semaglutide Enters the Picture

Here's where it gets complicated, and where most online comparisons get lazy.

Compounded semaglutide is prepared by a licensed compounding pharmacy under a patient-specific clinician prescription. It uses the same active ingredient as Ozempic and Wegovy. It is not FDA-approved. It has not been tested in randomized controlled trials at the same scale as the branded products. The clinical evidence for semaglutide as a molecule comes from the SUSTAIN, STEP, and SELECT programs, all conducted with branded formulations.

So what does that mean practically? Three things:

Access. Branded Ozempic and Wegovy require insurance coverage or out-of-pocket payment near list price, which can run over $1,000 per month. Compounded semaglutide operates under a different cost structure. For patients like David in Phoenix, whose insurance approved the less effective molecule but denied the one with stronger data, a compounded preparation of semaglutide may offer an alternative path to the molecule they actually want.

Dose flexibility. The branded pens come in fixed doses. Compounded programs can adjust dosing more granularly, which matters during titration and for patients who are sensitive to GI side effects at standard escalation schedules.

Regulatory reality. Compounding pharmacies operate under 503A or 503B frameworks with different manufacturing oversight than FDA-approved products. This is not a trivial distinction, and patients should understand it. The active ingredient is the same. The regulatory pathway, the quality assurance infrastructure, and the scale of evidence are not.

The most honest framing I can offer: compounded semaglutide is neither equivalent to nor inferior to branded semaglutide in some categorical sense. The molecule is the molecule. Everything around the molecule (manufacturing standards, regulatory scrutiny, clinical trial evidence for that specific preparation) differs. That's a conversation for you and your prescriber, not a Reddit thread.

What Patients Consistently Get Wrong

A few misconceptions show up so often they're worth addressing directly.

"More nausea means it's working better." Trial data from STEP-1 and STEP-3 do not support this. Patients with mild GI side effects and patients with significant nausea both achieved meaningful weight loss. Side effect intensity is not a proxy for efficacy.

"The medication does all the work." STEP-3's results compared to STEP-1 tell a clear story: adding structured lifestyle intervention to semaglutide produced more weight loss than medication alone. If you're on GLP-1 therapy and eating 1,400 calories a day, every one of those calories carries more nutritional weight than it did when you were eating 2,200. What you eat on therapy matters more, not less.

"Compounded semaglutide is basically the same as Ozempic." Same active ingredient? Yes. Same FDA regulatory status? No. Same clinical trial validation for that specific preparation? No. These distinctions matter, and flattening them in either direction (treating compounded as identical, or dismissing it as sketchy) is intellectually lazy.

"I can just stop when I hit my goal weight." STEP-4 documented what happens. Chronic weight regulation biology doesn't negotiate with your timeline.

How to Actually Think About This Decision

The trulicity vs ozempic question has a relatively clear clinical answer: semaglutide outperformed dulaglutide in head-to-head data on both glycemic control and weight loss, and it has a broader evidence base for cardiovascular benefit in patients with obesity. If you have a free choice between them, the data favor semaglutide.

But patients rarely have a free choice. Insurance formularies, prior authorization denials, supply shortages, and cost all constrain the decision. That's the real-world context in which compounded semaglutide becomes relevant: patients who want access to the semaglutide molecule but can't get it through branded channels at a price or timeline that works for them.

The clinician relationship matters more than the brand of program. A telehealth service that supports honest clinical conversation, responds to side effects with appropriate dose adjustments, and provides clear follow-up between refills produces better outcomes than one with slicker marketing and weaker clinical infrastructure. That's not a platitude. It's what the variance in real-world outcomes keeps pointing toward.

Adjacent Reading

Where This Fits

This article is part of the Compounded Semaglutide vs Ozempic and Wegovy cluster. For a broader treatment of the molecule, the regulatory pathway, the 503A and 503B compounding framework, and the clinical evidence base, the compounded semaglutide pillar guide is the primary reference on this site.

Frequently Asked Questions

Is compounded semaglutide the same as Ozempic or Wegovy?

Compounded semaglutide uses the same active ingredient: semaglutide. It is prepared by a licensed compounding pharmacy under a clinician prescription and is not FDA-approved. Wegovy and Ozempic are FDA-approved branded products manufactured by Novo Nordisk. Same molecule, different regulatory and manufacturing pathways.

What clinical evidence applies to compounded semaglutide?

The trial evidence for semaglutide as a molecule comes from the SUSTAIN, STEP, and SELECT programs, all conducted with branded formulations. Compounded preparations have not undergone equivalent randomized trials. The assumption (reasonable but unproven at the same evidentiary standard) is that the same molecule produces similar effects.

How does semaglutide compare to dulaglutide in clinical trials?

In the SUSTAIN-7 head-to-head trial, semaglutide 1.0 mg weekly outperformed dulaglutide 1.5 mg weekly on both A1c reduction and weight loss over 40 weeks. Both had predominantly GI side effects. Semaglutide also has weight-management-specific trial data (STEP program) and cardiovascular outcomes data in non-diabetic obesity patients (SELECT) that dulaglutide does not.

Can patients switch between compounded and branded semaglutide?

Yes, but it's a clinical decision supervised by the prescriber. Dose mapping, tolerability, timing, and the reason for switching all factor in. It's not a simple swap.

Why would someone choose compounded semaglutide over branded Ozempic?

Usually cost or access. Branded semaglutide can exceed $1,000 per month without insurance coverage, and insurance denials are common. Compounded semaglutide offers a different cost structure and is available when branded supply is constrained. The tradeoff is the absence of FDA approval for the compounded preparation.

Does nausea predict how much weight I'll lose?

No. STEP-1 and STEP-3 data show that meaningful weight loss occurred across the spectrum of GI tolerability. Some patients lose significant weight with minimal nausea. Side effects are a tolerability issue, not a performance indicator.

What happens if I stop semaglutide?

STEP-4 showed partial weight regain over 48 weeks after discontinuation. This is consistent with obesity as a chronic condition. The biology of weight regulation trends back toward baseline without ongoing treatment, similar to how blood pressure rises again if antihypertensive medication is stopped.

Compliance and Authorship

This article references the STEP-1, STEP-3, STEP-4, SUSTAIN-7, SUSTAIN-6, SELECT, and LEADER clinical trial programs where appropriate. It is intended as patient education and does not replace consultation with a licensed clinician.